Ambros Therapeutics is a clinical-stage biotechnology company.
Ambros Therapeutics has raised $125.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.
Ambros Therapeutics's investors include RA Capital Management, Balyasny Asset Management, Janus Henderson Investors, Adage Capital Management, Patient Square Capital.
Ambros Therapeutics is headquartered in Irvine, United States.
Ambros Therapeutics is a clinical-stage biotechnology company.
Ambros Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ambros Therapeutics — Funding & Investors." VCBacked, December 16, 2025, https://www.vcbacked.co/company/ambros-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Ambros Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/ambros-therapeutics
{{cite web |title=Ambros Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ambros-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated